Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
BJU International|May 6, 2019
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancerMarzia Del Re, Stefania Crucitta, Andrea Sbrana, et al.
Journal of Translational Medicine|August 16, 2022
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsMarzia Del Re, Stefania Crucitta, Federico Paolieri, et al.
Vaccines|June 24, 2022
Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective AnalysisAmedeo Nuzzo, Simona Manacorda, Enrico Sammarco, et al.
Clinical Genitourinary Cancer|May 17, 2024
Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic AlgorithmFederico Paolieri, Enrico Sammarco, Marco Ferrari, et al.
Cells|June 19, 2024
First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group AlgorithmFrancesco Bloise, Fiorella Manfredi, Luca Zatteri, et al.
Expert Review of Anticancer Therapy|May 21, 2025
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancerGianluca Ingrosso, Andrea Lancia, Lilia Bardoscia, et al.
Clinical Genitourinary Cancer|June 29, 2022
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or CabozantinibRoberto Iacovelli, Chiara Ciccarese, Marco Maruzzo, et al.
Cancers|May 14, 2022
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian StudyUmberto Basso, Federico Paolieri, Mimma Rizzo, et al.
Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Pageof 3